FX.co ★ Castle Biosciences Expects To Meet Or Exceed Top End Of FY24 Revenue Guidance

Castle Biosciences Inc. (CSTL) has announced its expectation to either meet or surpass the upper limit of its projected revenue for the fiscal year 2024, which is set between $320 million and $330 million. This accomplishment underscores the company's dedication to providing value to its shareholders, while also advancing its mission to enhance healthcare outcomes through innovative diagnostic tests that facilitate patient care.

In the fourth quarter of 2024, Castle Biosciences reported the distribution of 24,071 test reports, a notable increase from the 20,284 reports issued during the same time frame in 2023. Over the entire year of 2024, the company delivered a total of 96,071 test reports, significantly up from the 70,429 reports in 2023.